

Applicants: Ann Marie Schmidt and David Stern
U.S. Serial No.: 09/166,649
Filing Date: October 5, 1998
Page 2

Please amend the subject application as follows:

In the claims:

Please amend claim 29 under the provisions of 37 C.F.R. §1.121(c) as follows. A marked up version of amended claim 29 wherein the deleted material is in brackets and the inserted material is underlined is attached hereto as Exhibit A.

--29. (Amended) The method of claim 1, wherein step (a) occurs *in vitro* or *in vivo*--

REMARKS

Claims 1, 2, 4-8, 11-13, 15, 17, 18, 20-22, 24-29 and 58-59 are pending in the instant application. Applicants have hereinabove amended claim 29. This amendment does not involve any issue of new matter. Support for this amendment may be found *inter alia* as follows: claim 29: page 9, line 20; claim 58: page 9, lines 23-24. Therefore, entry of this amendment is respectfully requested such that claims 1, 2, 4-8, 11-13, 15, 17, 18, 20-22, 24-29 and 58 will be pending.

Rejection under 35 U.S.C. § 112, first paragraph

Claims 11-12

The Examiner maintained the rejection of claims 11 and 12 under 35 U.S.C. §112, first paragraph, alleging that the specification, while being enabling for a method for determining whether a compound is capable of inhibiting the interaction of a peptide with